November 2019—The Centers for Medicare and Medicaid Services granted approval for a new technology add-on payment (NTAP) to T2 Biosystems’ T2Bacteria Panel, for fiscal year 2020. The T2Bacteria Panel is the first in vitro diagnostic test to receive approval for NTAP, according to the company.
Effective Oct. 1, 2019, Medicare will provide an add-on payment for the T2Bacteria Panel of up to $97.50 per qualifying case to Inpatient Prospective Payment System–participating acute care hospitals. This add-on payment will be incremental to the Medicare Severity Diagnosis Related Group reimbursement for qualifying Medicare inpatient cases based on the cost of the case.
The T2Bacteria Panel is an FDA-cleared, direct from blood bacteria pathogen identification test that does not require blood culture. The panel detects five major bacterial pathogens associated with sepsis directly from whole blood in three to five hours. It runs on the company’s T2Dx Instrument.
T2 Biosystems, 781-457-1200